Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
News|Articles|September 2, 2015
- Pharmaceutical Technology-09-02-2015
- Volume 39
- Issue 9
Fluid Bed Agglomerator Offers Controlled Formation
Kason’s Vibro-Bed fluid-bed agglomerator is equipped with imbalanced-weight gyratory motors and mounted on a spring suspension.
Kason’s Vibro-Bed fluid-bed agglomerator is equipped with imbalanced-weight gyratory motors and mounted on a spring suspension. Inherent rigidity of the circular unit allows materials of construction to be downgauged and vibratory motors to be downsized. Caster-mounted frames require only on-site connections to a power source, dust collector, and material inlet/outlet can be preconfigured.
Units are offered in diameters from 460 to 2135 mm, encompassing laboratory to commercial capacity batch and continuous applications. All can also be configured for dedicated powder-coating applications as well as fluid-bed drying, cooling, or moisturizing.
Kason Corporation
Articles in this issue
about 11 years ago
Generating Savings from Room Declassificationabout 11 years ago
Cleaning a Vial Filling Lineabout 11 years ago
Establishing Limits for Dermal Absorption of Elemental Impuritiesabout 11 years ago
A Matter of Tasteabout 11 years ago
CMOs Concerned With Cost of Single-Use Equipmentabout 11 years ago
Manufacturers Face Key Policy and Regulatory Challengesabout 11 years ago
Getting Flexible with Manufacturingabout 11 years ago
Computerized Systems Validationabout 11 years ago
Collaborating on GMP Inspectionsabout 11 years ago
Going Low TemperatureRelated to this article
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5